Granules India gets USFDA approval for Metoprolol Succinate ER tablets
SUMMARY:
– Granules India share prices have been continuously falling, reaching 279 INR on 13th June 2023.
– However, the share has gone up again to 284 INR after the recent news.
– The USFDA has approved Granules India’s ANDA, which is good news for the company.
Granules India, a pharmaceutical company, has been facing a continuous decline in its share prices for the past year. In the last month alone, the share has fallen by 5%. From January to June, the share price has fallen by 11%. However, there is good news for the company as the USFDA has approved its ANDA.
The ANDA approval is for the company’s Metoprolol Succinate ER tablets. The total annual sales of this hypertension drug are worth 2,632 crore INR. This approval is likely to boost the company’s financials and improve investor sentiment.
The company’s share prices have gone up again to 284 INR after the recent news. This is a positive sign for the company, considering the continuous decline in share prices.
In summary, Granules India has received USFDA approval for its ANDA, which is good news for the company. The Metoprolol Succinate ER tablets are expected to have annual sales worth 2,632 crore INR. After the recent news, the company’s share prices have gone up to 284 INR.
Follow DelhiBreakings on Google News
Superfast News Coverage by DelhiBreakings.com team.
For Superfast national news and Delhi Breaking Stories visit us daily at https://delhibreakings.com
